AI Fuels Biotech M&A Boom in 2026
AI-driven drug discovery, lower rates and a looming patent cliff are set to accelerate biotech M&A in 2026. What investors and executives should watch.
AI Fuels Biotech M&A Boom in 2026 Read More »
News
UK Healthcare and AI: FDP Shortfalls and Practical Operational Gains
How the NHS Federated Data Platform, local ICBs and AI tools are shaping demand-capacity monitoring, operational decisions and system-wide improvements.
UK Healthcare and AI: FDP Shortfalls and Practical Operational Gains Read More »
AI-Powered Molecular Sensors for Ultra-Early Cancer Detection — CleaveNet, MIT & Microsoft
CleaveNet leverages AI to design protease-targeting molecular sensors that reveal cancer signals in urine, opening paths to earlier, lower-cost, decentralized diagnostics.
AI Giants Unveil New Healthcare Tools: Innovation Meets Critical Scrutiny
Anthropic and Google have launched new AI tools for clinical settings. Compare Claude for Healthcare, Google’s MedGemma 1.5 and OpenAI’s ChatGPT Health, and learn about safety, regulation, and how AI is likely to support clinicians.
AI Giants Unveil New Healthcare Tools: Innovation Meets Critical Scrutiny Read More »
AI Giants Enter Healthcare: What ChatGPT Health, MedGemma and Claude Mean for Diagnostics
OpenAI, Google and Anthropic launch medical AI tools aimed at developers and enterprise workflows. What this means for diagnostics, regulation, and health AI strategy.
RCP Report: Practical Roadmap for AI and Digital Care in the NHS
The Royal College of Physicians sets out what the NHS needs to adopt AI safely: digital standards, a central approval bank, clinician-led regulation, and workforce training.
RCP Report: Practical Roadmap for AI and Digital Care in the NHS Read More »
AI-Designed Drug Enters Human Trials: What This Means for Pharma and Patients
An AI-designed molecule has moved into Phase 1 trials after a high-profile partnership and funding round. What this milestone means for drug timelines, investors, and patients.
AI-Designed Drug Enters Human Trials: What This Means for Pharma and Patients Read More »
Multimodal AI Is Changing Early Cancer Detection: What Clinicians Need to Know
Multimodal AI is improving early cancer detection, drug discovery, and clinical workflows. A concise update on benefits, risks, and next steps for clinicians.
Multimodal AI Is Changing Early Cancer Detection: What Clinicians Need to Know Read More »
Qureight Appoints Rebecca Simmons as COO to Scale AI Imaging and Clinical Data
Rebecca Simmons joins Qureight as COO to drive global growth of its AI CT imaging biomarkers and clinical data platform for lung and heart disease.
Qureight Appoints Rebecca Simmons as COO to Scale AI Imaging and Clinical Data Read More »
Regulating Healthcare AI: Balancing Innovation, Safety, and Equity
A concise overview of why healthcare AI needs regulation, the gaps in current oversight, and collaborative models like assurance labs to promote fair, safe adoption.
Regulating Healthcare AI: Balancing Innovation, Safety, and Equity Read More »